Cited by 1,010Cytokine Signaling Pathways and InteractionsNF-κB Signaling PathwaysProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 182 of the 184 references it cites were found in a registry or an index.

The role of JAK/STAT signaling pathway and its inhibitors in diseases.

Xin, Ping, Xu, Xiaoyun, Deng, Chengjie, Liu, Shuang, Wang, Youzhi, Zhou, Xuegang, Ma, Hongxing, Wei, Donghua, Sun, Shiqin·2020·International Immunopharmacology

DOI 10.1016/j.intimp.2020.106210

Open this paper in CoChat — free account

Abstract

The JAK/STAT signaling pathway is an universally expressed intracellular signal transduction pathway and involved in many crucial biological processes, including cell proliferation, differentiation, apoptosis, and immune regulation. It provides a direct mechanism for extracellular factors-regulated gene expression. Current researches on this pathway have been focusing on the inflammatory and neoplastic diseases and related drug. The mechanism of JAK/STAT signaling is relatively simple. However, the biological consequences of the pathway are complicated due to its crosstalk with other signaling pathways. In addition, there is increasing evidence indicates that the persistent activation of JAK/STAT signaling pathway is closely related to many immune and inflammatory diseases, yet the specific mechanism remains unclear. Therefore, it is necessary to study the detailed mechanisms of JAK/STAT signaling in disease formation to provide critical reference for clinical treatments of the diseases. In this review, we focus on the structure of JAKs and STATs, the JAK/STAT signaling pathway and its negative regulators, the associated diseases, and the JAK inhibitors for the clinical therapy.

Integrity signals

Registry

Crossref · 10.1016/j.intimp.2020.106210

Cites

182 of 182 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: MicroRNA-30e promotes hepatocyte proliferation and inhibits apoptosis in cecal ligation and puncture-induced sepsis through the JAK/STAT signaling pathway by binding to FOSL2
Ling, L., Zhang, S., Zhi, L.-D., Li, H., Wen, Q.-K., Li, G., & Zhang, W. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.042 · Cited by 31
Retracted
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
STATs and Gene Regulation
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Rheumatoid arthritis
Scott, D. L., Wolfe, F., & Huizinga, T. W. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60826-4 · Cited by 3,263
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · Nature Reviews Immunology · doi:10.1038/nri3552 · Cited by 2,772
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
Lotze, M. T., & Tracey, K. J. (2005) · Nature reviews. Immunology · doi:10.1038/nri1594 · Cited by 2,490
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Epidemiology of Parkinson’s disease
Tysnes, O., & Storstein, A. M. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1686-y · Cited by 2,437
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
A family of cytokine-inducible inhibitors of signalling
Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., et al. (1997) · Nature · doi:10.1038/43206 · Cited by 2,066
Intestinal homeostasis and its breakdown in inflammatory bowel disease
Maloy, K. J., & Powrie, F. M. (2011) · Nature · doi:10.1038/nature10208 · Cited by 1,911
Protein Tyrosine Phosphatases in the Human Genome
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., & Mustelin, T. (2004) · Cell · doi:10.1016/j.cell.2004.05.018 · Cited by 1,886
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O’Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. D. J. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,670
SOCS proteins, cytokine signalling and immune regulation
Yoshimura, A., Naka, T., & Kubo, M. (2007) · Nature Reviews Immunology · doi:10.1038/nri2093 · Cited by 1,580
The JAK-STAT Pathway at Twenty
Stark, G. R., & Darnell, J. E., Jr. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.013 · Cited by 1,577
Regulation of JAK–STAT signalling in the immune system
Shuai, K., & Liu, B. (2003) · Nature reviews. Immunology · doi:10.1038/nri1226 · Cited by 1,410
A new protein containing an SH2 domain that inhibits JAK kinases
Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H., et al. (1997) · Nature · doi:10.1038/43213 · Cited by 1,408
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
O’Shea, J. J., & Plenge, R. M. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.014 · Cited by 1,186
Role of P-Glycoprotein in Pharmacokinetics
Lin, J. H., & Yamazaki, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342010-00003 · Cited by 1,023
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., & Diefenbach, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.006 · Cited by 888
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608345 · Cited by 872
IL-6 in autoimmune disease and chronic inflammatory proliferative disease
Ishihara, K., & Hirano, T. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00027-8 · Cited by 807
The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells
Seif, F., Khoshmirsafa, M., Aazami, H., Mohsenzadegan, M., Sedighi, G. R., & Bahar, M. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0177-y · Cited by 799
Sepsis definitions: time for change
Vincent, J., Opal, S. M., Marshall, J. C., & Tracey, K. J. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61815-7 · Cited by 773
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Ghoreschi, K., Jesson, M. I., Xiong, L., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003668 · Cited by 651
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
Clark, J. D., Flanagan, M. E., & Telliez, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401490p · Cited by 632
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J. M., Zamani, O., Ludivico, C. L., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 632
Mechanisms of Jak/STAT Signaling in Immunity and Disease
Villarino, A. V., Kanno, Y., Ferdinand, J. R., & O’Shea, J. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401867 · Cited by 564
Estrogen Regulation of Growth Hormone Action
Leung, K., Johannsson, G., Leong, G. M., & Ho, K. K. Y. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0035 · Cited by 550
VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligasesPreprint
Kamura, T., Maenaka, K., Kotoshiba, S., Matsumoto, M., Kohda, D., Conaway, R., Conaway, J. W., & Nakayama, K. I. (2004) · Genes & Development · doi:10.1101/gad.1252404 · Cited by 487
Epidemiology of Parkinson's disease
Elbaz, A., Carcaillon‐Bentata, L., Kab, S., & Moisan, F. (2015) · Revue Neurologique · doi:10.1016/j.neurol.2015.09.012 · Cited by 487
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
Fridman, J. S., Scherle, P., Collins, R. J., Burn, T. C., Li, Y., Li, J., Covington, M. B., Thomas, B. A., Collier, P., Favata, M. F., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902819 · Cited by 472
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
Fleischmann, R., Schiff, M. H., van der Heijde, D. M. F. M., Ramos-Remus, C., Spindler, A. J., Stanislav, M., Zerbini, C. A. F., Gurbuz, S., Dickson, C. L., de Bono, S., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39953 · Cited by 429
PIAS Proteins Modulate Transcription Factors by Functioning as SUMO-1 Ligases
Kotaja, N., Karvonen, U., Jänne, O. A., & Palvimo, J. J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5222-5234.2002 · Cited by 426
MHCII Is Required for -Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneration
Harms, A. S., Cao, S., Rowse, A. L., Thome, A. D., Li, X., Mangieri, L. R., Cron, R. Q., Shacka, J. J., Raman, C., & Standaert, D. G. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5610-12.2013 · Cited by 406
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Dougados, M., van der Heijde, D. M. F. M., Chen, Y., Greenwald, M., Drescher, E., Liu, J., Beattie, S. D., Witt, S., de la Torre, I., Gaich, C. L., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210094 · Cited by 405
Cytokine‐inducible SH2 protein‐3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N‐terminal kinase inhibitory region as well as SH2 domain
Sasaki, A., Yasukawa, H., Suzuki, A., Kamizono, S., Syoda, T., Kinjyo, I., Sasaki, M., Johnston, J. A., & Yoshimura, A. (1999) · Genes to Cells · doi:10.1046/j.1365-2443.1999.00263.x · Cited by 398
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.038 · Cited by 384
Mini‐review: The nuclear protein HMGB1 as a proinflammatory mediator
Harris, H. E., & Andersson, U. (2004) · European Journal of Immunology · doi:10.1002/eji.200424916 · Cited by 377
Interleukin-6 as a key player in systemic inflammation and joint destruction
Fonseca, J. E., Santos, M. J., Canhão, H. M., & Choy, E. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.01.012 · Cited by 376
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Hodge, J. A., Kawabata, T. T., Krishnaswami, S., Clark, J. D., Telliez, J., Dowty, M. E., Menon, S. S., Lamba, M., & Zwillich, S. H. (2016) · PubMed · Cited by 374
The myocardial JAK/STAT pathway: From protection to failure
Boengler, K., Hilfiker‐Kleiner, D., Drexler, H., Heusch, G., & Schulz, R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.002 · Cited by 373
The IL-6/sIL-6R complex as a novel target for therapeutic approaches
Rose‐John, S., Waetzig, G. H., Scheller, J., Grötzinger, J., & Seegert, D. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.5.613 · Cited by 364
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
Papp, K. A., Menter, A., Abe, M., Elewski, B. E., Feldman, S. R., Gottlieb, A. B., Langley, R. G. B., Luger, T. A., Thaçi, D., Buonanno, M., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14018 · Cited by 326
Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases
Yan, Z., Gibson, S. A., Buckley, J. A., Qin, H., & Benveniste, E. N. (2018) · Clinical Immunology · doi:10.1016/j.clim.2016.09.014 · Cited by 318
A new modality for immunosuppression: targeting the JAK/STAT pathway
O’Shea, J. J., Pesu, M., Borie, D. C., & Changelian, P. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1441 · Cited by 305
The role of the JAK/STAT signal pathway in rheumatoid arthritis
Malemud, C. J. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x18776224 · Cited by 303
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
Boyle, D. L., Soma, K., Hodge, J., Kavanaugh, A., Mandel, D. R., Mease, P. J., Shurmur, R., Singhal, A. K., Wei, N., Rosengren, S., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206028 · Cited by 302
Sepsis 2018: Definitions and Guideline Changes
Napolitano, L. M. (2018) · Surgical Infections · doi:10.1089/sur.2017.278 · Cited by 288
Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration
Qin, H., Buckley, J. A., Li, X., Liu, Y., Fox, T. H., Meares, G. P., Yu, H., Yan, Z., Harms, A. S., Li, Y., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4658-15.2016 · Cited by 285
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans
Dowty, M. E., Lin, J., Ryder, T. F., Wang, W., Walker, G. S., Vaz, A. D. N., Chan, G. L., Krishnaswami, S., & Prakash, C. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054940 · Cited by 279
Cardiovascular disease in autoimmune rheumatic diseases
Hollan, I., Meroni, P. L., Ahearn, J. M., Tervaert, J. W. C., Curran, S., Goodyear, C. S., Hestad, K. A., Kahaleh, B., Riggio, M. P., Shields, K. J., et al. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.03.013 · Cited by 278
Cytokines, STATs and liver disease.
Gao, B. (2005) · PubMed · Cited by 274
Reflecting on the global burden of musculoskeletal conditions: lessons learnt from the Global Burden of Disease 2010 Study and the next steps forward
Hoy, D. G., Smith, E. U. R., Cross, M., Sànchez-Riera, L., Blyth, F., Buchbinder, R., Woolf, A. D., Driscoll, T., Brooks, P., & MARCH, L. M. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205393 · Cited by 270
Oclacitinib ( APOQUEL ® ) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy
Gonzales, A. J., Bowman, J. W., Fici, G. J., Zhang, M., Mann, D. W., & Mitton‐Fry, M. J. (2014) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12101 · Cited by 265
Role of the JAK–STAT Pathway in Protection Against Myocardial Ischemia/Reperfusion Injury
Bolli, R., Dawn, B., & Xuan, Y. (2003) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(02)00230-x · Cited by 238
Prevalence of rheumatoid arthritis in low- and middle-income countries: A systematic review and analysis.
Rudan, I., Sidhu, S., Papana, A., Meng, S., Xinwei, Y., Wang, W., Campbell–Page, R. M., Demaio, S., Nair, H., Sridhar, D., et al. (2015) · Europe PMC (PubMed Central) · doi:10.7189/jogh.05.010409 · Cited by 237
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Pardanani, A. D., Laborde, R. R., Lasho, T. L., Finke, C. M., Begna, K. H., Al‐Kali, A., Hogan, W. J., Litzow, M. R., Leontovich, A. A., Kowalski, M. M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.71 · Cited by 236
Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
Rompaey, L. V., Galien, R., van der Aar, E. M., Clément-Lacroix, P., Nelles, L., Smets, B., Lepescheux, L., Christophe, T., Conrath, K., Vandeghinste, N., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201348 · Cited by 235
Multiple regulation pathways and pivotal biological functions of STAT3 in cancer
Yuan, J., Zhang, F., & Niu, R. (2015) · Scientific Reports · doi:10.1038/srep17663 · Cited by 235
Regulation of cytokine signaling pathways by PIAS proteins
Shuai, K. (2006) · Cell Research · doi:10.1038/sj.cr.7310027 · Cited by 228
Signaling pathways involved in MDSC regulation
Trikha, P., & Carson, W. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.003 · Cited by 207
Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Genovese, M. C., Smolen, J. S., Weinblatt, M. E., Burmester, G. R., Meerwein, S., Camp, H. S., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39808 · Cited by 204
SAF-Box, a Conserved Protein Domain That Specifically Recognizes Scaffold Attachment Region DNA
Kipp, M., Göhring, F., Ostendorp, T., van Drunen, C. M., DRIEL, R. V., Przybylski, M., & Fackelmayer, F. O. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.20.7480-7489.2000 · Cited by 194
JAK/STAT/SOCS‐signaling pathway and colon and rectal cancer
Slattery, M. L., Lundgreen, A., Kadlubar, S. A., Bondurant, K. L., & Wolff, R. K. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.21841 · Cited by 192
The innate immune system in demyelinating disease
Mayo, L., Quintana, F. J., & Weiner, H. L. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01135.x · Cited by 192
Baricitinib: First Global Approval
Markham, A. (2017) · Drugs · doi:10.1007/s40265-017-0723-3 · Cited by 187
SOCS proteins in development and disease.
Trengove, M. C., & Ward, A. C. (2013) · Europe PMC (PubMed Central) · Cited by 185
The many faces of the SOCS box
Piessevaux, J., Lavens, D., Peelman, F., & Tavernier, J. H. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.08.006 · Cited by 183
A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy
Kremer, J. M., Emery, P., Camp, H. S., Friedman, A., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., Jungerwirth, S., & Keystone, E. C. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39801 · Cited by 183
PIAS proteins promote SUMO-1 conjugation to STAT1
Ungureanu, D., Vanhatupa, S., Kotaja, N., Yang, J., Aittomäki, S., Jänne, O. A., Palvimo, J. J., & Silvennoinen, O. (2003) · Blood · doi:10.1182/blood-2002-12-3816 · Cited by 167
Astaxanthin Inhibits JAK/STAT-3 Signaling to Abrogate Cell Proliferation, Invasion and Angiogenesis in a Hamster Model of Oral Cancer
Kowshik, J., Baba, A. B., Giri, H., Reddy, G. D., Dixit, M., & Nagini, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109114 · Cited by 165
Negative regulation of cytokine signaling and immune responses by SOCS proteins.
Yoshimura, A., Nishinakamura, H., Matsumura, Y., & Hanada, T. (2005) · Arthritis Research · doi:10.1186/ar1741 · Cited by 165
Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management
Tefferi, A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24592 · Cited by 163
Signaling by STATs.
Ivashkiv, L. B., & Hu, X. (2004) · Arthritis Research · doi:10.1186/ar1197 · Cited by 160
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
Papp, K. A., Krueger, J. G., Feldman, S. R., Langley, R. G. B., Thaçi, D., Torii, H., Tyring, S. K., Wolk, R. A., Gardner, A., Mebus, C., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.01.013 · Cited by 157
Therapeutic Efficacy of Suppressing the JAK/STAT Pathway in Multiple Models of Experimental Autoimmune Encephalomyelitis
Liu, Y., Holdbrooks, A. T., Sarno, P. D., Rowse, A. L., Yanagisawa, L. L., McFarland, B. C., Harrington, L. E., Raman, C., Sabbaj, S., Benveniste, E. N., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301513 · Cited by 155
Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary
Lopez-Diego, R. S., & Weiner, H. L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2358 · Cited by 154
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Takeuchi, T., Tanaka, Y., Iwasaki, M., Ishikura, H., Saeki, S., & Kaneko, Y. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208279 · Cited by 151
SOCS-6 Binds to Insulin Receptor Substrate 4, and Mice Lacking the SOCS-6 Gene Exhibit Mild Growth Retardation
Krebs, D. L., Uren, R. T., Metcalf, D., Rakar, S., Zhang, J., Starr, R., Souza, D. P. D., Hanzinikolas, K., Eyles, J. L., Connolly, L., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.13.4567-4578.2002 · Cited by 150
Established and novel disease‐modifying treatments in multiple sclerosis
Cross, A. H., & Naismith, R. T. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12203 · Cited by 142
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production
LaBranche, T. P., Jesson, M. I., Radi, Z. A., Storer, C. E., Guzova, J. A., Bonar, S. L., Thompson, J., Happa, F. A., Stewart, Z. S., Zhan, Y., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34649 · Cited by 141
Interleukin‐31: its role in canine pruritus and naturally occurring canine atopic dermatitis
Gonzales, A. J., Humphrey, W. R., Messamore, J. E., Fleck, T. J., Fici, G. J., Shelly, J. A., Teel, J. F., Bammert, G. F., Dunham, S. A., Fuller, T. E., et al. (2013) · Veterinary Dermatology · doi:10.1111/j.1365-3164.2012.01098.x · Cited by 139
The Specific Roles of JAK/STAT Signaling Pathway in Sepsis
Cai, B., Cai, J., Luo, Y., Chen, C., & Zhang, S. (2015) · Inflammation · doi:10.1007/s10753-015-0135-z · Cited by 138
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
Namour, F., Diderichsen, P. M., Cox, E. H., Vayssière, B., der Aa, A. V., Tasset, C. T., & Klooster, G. A. E. V. '. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0240-z · Cited by 138
Chemical and Mechanistic Approaches to the Study of Protein Tyrosine Phosphatases
Zhang, Z.-Y. (2003) · Accounts of Chemical Research · doi:10.1021/ar020122r · Cited by 138
New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis
English, C., & Aloi, J. J. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.03.001 · Cited by 132
The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease
Schapansky, J., Nardozzi, J. D., & LaVoie, M. J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.049 · Cited by 132
Structure of the SOCS4-ElonginB/C Complex Reveals a Distinct SOCS Box Interface and the Molecular Basis for SOCS-Dependent EGFR Degradation
Bullock, A. N., Rodríguez, M. C., Debreczeni, J. E., Songyang, Z., & Knapp, S. (2007) · Structure · doi:10.1016/j.str.2007.09.016 · Cited by 131
Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases
Yu, Z.-H., & Zhang, Z. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00105 · Cited by 131
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
Singer, J. W., Al‐Fayoumi, S., Ma, H., Komrokji, R. S., Mesa, R. A., & Verstovšek, S. (2016) · Journal of Experimental Pharmacology · doi:10.2147/jep.s110702 · Cited by 130
Self-citation
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)
Zhou, T., Georgeon, S., Moser, R., Moore, D. J., Caflisch, A., & Hantschel, O. D. (2013) · Leukemia · doi:10.1038/leu.2013.205 · Cited by 126
Luteolin suppresses the JAK/STAT pathway in a cellular model of intestinal inflammation
Nunes, C., Almeida, L. M., Barbosa, R. M., & Laranjinha, J. A. N. (2016) · Food & Function · doi:10.1039/c6fo01529h · Cited by 126
STATs: An Old Story, Yet Mesmerizing
Saeid, A., Saki, N., Ahmadvand, M., Asghari, F., Salari, F., & Rahim, F. (2016) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 124
Swertiamarin attenuates inflammation mediators via modulating NF-κB/I κB and JAK2/STAT3 transcription factors in adjuvant induced arthritis
Saravanan, S., Islam, V. I. H., Narasimhan, P. B., Pandikumar, P., Thirugnanasambantham, K., Chellappandian, M., Raj, C. S. D., Paulraj, M. G., & Savarimuthu Ignacimuthu, S. J. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.005 · Cited by 121
Therapeutic targets for rheumatoid arthritis: Progress and promises
Alghasham, A., & Rasheed, Z. (2014) · Autoimmunity · doi:10.3109/08916934.2013.873413 · Cited by 118
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
Papp, K. A., Pariser, D. M., Catlin, M., Wierz, G., Ball, G., Akinlade, B., Zeiher, B. G., & Krueger, J. G. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13745 · Cited by 117
The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels
Isomäki, P., Junttila, I., Vidqvist, K.-L., Korpela, M. M., & Silvennoinen, O. (2014) · Rheumatology · doi:10.1093/rheumatology/keu430 · Cited by 117
Involvement of the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway in Multiple Sclerosis and the Animal Model of Experimental Autoimmune Encephalomyelitis
Benveniste, E. N., Liu, Y., McFarland, B. C., & Qin, H. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0012 · Cited by 117
Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
Mohamed, M. F., Camp, H. S., Jiang, P. X., Padley, R. J., Asatryan, A., & Othman, A. A. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0419-y · Cited by 117
Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy
Chikuma, S., Kanamori, M., Mise‐Omata, S., & Yoshimura, A. (2017) · Cancer Science · doi:10.1111/cas.13194 · Cited by 112
Clinical correlation of peripheral CD4+-cell sub-sets, their imbalance and Parkinson's disease
Chen, Y., Qi, B.-Q., Xu, W., MA, B., Li, L., Chen, Q., Qian, W., Liu, X., & Qu, H. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4136 · Cited by 110
Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Malemud, C. J., & Pearlman, E. M. (2009) · Current Signal Transduction Therapy · doi:10.2174/157436209789057467 · Cited by 103
Does ruxolitinib prolong the survival of patients with myelofibrosis?
Cervantes, F., & Pereira, A. (2016) · Blood · doi:10.1182/blood-2016-11-731604 · Cited by 101
A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model
Ito, M., Yamazaki, S., Yamagami, K., Kuno, M., Morita, Y., Okuma, K., Nakamura, K., Chida, N., Inami, M., Inoue, T., et al. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.12.001 · Cited by 96
Proinflammatory Cytokine IL‐6 and JAK‐STAT Signaling Pathway in Myeloproliferative Neoplasms
Čokić, V. P., Ajtić, O. M., Beleslin‐Čokić, B. B., Marković, D. C., Kovačić, M. V., Diklić, M., Kraguljac‐Kurtović, N., Damjanovic, S. S., Milenković, P., Gotić, M., et al. (2015) · Mediators of Inflammation · doi:10.1155/2015/453020 · Cited by 92
Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer
Zundler, S., & Neurath, M. F. (2016) · Vaccines · doi:10.3390/vaccines4010005 · Cited by 90
SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?
Mahony, R., Ahmed, S., Diskin, C., & Stevenson, N. J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2234-x · Cited by 89
The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease
Holleran, G. E., Lopetuso, L. R., Petito, V., Graziani, C., Ianiro, G., McNamara, D. A., Gasbarrini, A., & Scaldaferri, F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102020 · Cited by 88
Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling
Macha, M. A., Rachagani, S., Gupta, S., Pai, P., Ponnusamy, M. P., Batra, S. K., & Jain, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.037 · Cited by 87
Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence
Storelli, E., Cassina, N., Rasini, E., Marino, F., & Cosentino, M. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00013 · Cited by 87
JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases
Gao, Q., Liang, X., Shaikh, A. S., Zang, J., Xu, W., & Zhang, Y. (2017) · Current Drug Targets · doi:10.2174/1389450117666161207163054 · Cited by 84
Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
Klünder, B., Mohamed, M.-E. F., & Othman, A. A. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0605-6 · Cited by 83
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis
Nakayamada, S., Kubo, S., Iwata, S., & Tanaka, Y. (2016) · BioDrugs · doi:10.1007/s40259-016-0190-5 · Cited by 77
Interleukin 17 regulates SHP-2 and IL-17RA/STAT-3 dependent Cyr61, IL-23 and GM-CSF expression and RANKL mediated osteoclastogenesis by fibroblast-like synoviocytes in rheumatoid arthritis
Ramamoorthi, G., & Rasool, M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.09.003 · Cited by 76
Melittin enhances apoptosis through suppression of IL-6/sIL-6R complex-induced NF-κB and STAT3 activation and Bcl-2 expression for human fibroblast-like synoviocytes in rheumatoid arthritis
Kim, S., Park, K.-Y., Yoon, W.-C., Park, S., Park, K., Yoo, D., & Choe, J. (2011) · Joint Bone Spine · doi:10.1016/j.jbspin.2011.01.004 · Cited by 75
Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines
Sağlam, A. S. Y., Alp, E., Elmazoğlu, Z., & Menevşe, S. (2015) · Human & Experimental Toxicology · doi:10.1177/0960327115595686 · Cited by 74
Targeting oncogenic transcription factors: therapeutic implications of endogenous STAT inhibitors
Heppler, L. N., & Frank, D. A. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.10.004 · Cited by 74
Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma
Pérez, C., González‐Rincón, J., Onaindía, A., Almaráz, C., García‐Díaz, N., Pisonero, H., Curiel‐Olmo, S., Gómez, S., Cereceda, L., Madureira, R., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.132837 · Cited by 73
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials
D’Amico, F., Fiorino, G., Furfaro, F., Allocca, M., & Danese, S. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1492547 · Cited by 72
Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation
Boyle, K., Zhang, J., Nicholson, S. E., Trounson, E., Babon, J. J., McManus, E. J., Nicola, N. A., & Robb, L. G. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.11.002 · Cited by 69
Brief Report: T Cell Expression of Granulocyte–Macrophage Colony‐Stimulating Factor in Juvenile Arthritis Is Contingent Upon Th17 Plasticity
Piper, C. J. M., Pesenacker, A. M., Bending, D., Thirugnanabalan, B., Varsani, H., Wedderburn, L. R., & Nistala, K. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38647 · Cited by 68
17β-Oestradiol enhances the expansion and activation of myeloid-derived suppressor cells via signal transducer and activator of transcription (STAT)−3 signalling in human pregnancy
Pan, T. S., Li, Z., Wu, S., Cao, Y., Yang, Q., Cai, Z., Cai, X., Zhao, W., Ma, N., Zhang, W., et al. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12790 · Cited by 67
IL‐31‐induced pruritus in dogs: a novel experimental model to evaluate anti‐pruritic effects of canine therapeutics
Gonzales, A. J., Fleck, T. J., Humphrey, W. R., Galvan, B. A., Aleo, M. M., Mahabir, S. P., Tena, J., Greenwood, K. G., & McCall, R. B. (2015) · Veterinary Dermatology · doi:10.1111/vde.12280 · Cited by 66
Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators?
Speirs, C., Williams, J. J. L., Riches‐Suman, K., Salt, I. P., & Palmer, T. M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.10.001 · Cited by 61
Understanding the role of SOCS signaling in neurodegenerative diseases: Current and emerging concepts
Cianciulli, A., Calvello, R., Porro, C., Trotta, T., & Panaro, M. A. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.07.005 · Cited by 59
Momelotinib therapy for myelofibrosis: a 7-year follow-up
Tefferi, A., Barraco, D., Lasho, T. L., Shah, S. H., Begna, K. H., Al‐Kali, A., Hogan, W. J., Litzow, M. R., Hanson, C. A., Ketterling, R. P., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0067-6 · Cited by 59
Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions
Namour, F., Desrivot, J., der Aa, A. V., Harrison, P., Tasset, C. T., & Klooster, G. A. E. V. '. (2016) · Drug Metabolism Letters · doi:10.2174/1872312810666151223103353 · Cited by 55
Retinoic acid amide inhibits JAK/STAT pathway in lung cancer which leads to apoptosis
Li, H., Zhao, W., Shi, Y. P., Li, Y., Zhang, L., Zhang, H., & Wang, D. (2015) · Tumor Biology · doi:10.1007/s13277-015-3534-8 · Cited by 54
Are you experienced? Understanding bladder innate immunity in the context of recurrent urinary tract infection
O'Brien, V. P., Hannan, T. J., Schaeffer, A. J., & Hultgren, S. J. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000130 · Cited by 53
The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation
Ardoin, S. P., & Pisetsky, D. S. (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0054-z · Cited by 49
Matrine induces the apoptosis of fibroblast-like synoviocytes derived from rats with collagen-induced arthritis by suppressing the activation of the JAK/STAT signaling pathway
Yang, Y., Dong, Q., & Li, R. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2843 · Cited by 49
SOCS-1 Localizes to the Microtubule Organizing Complex-Associated 20S Proteasome
Vuong, B. Q., Arenzana, T. L., Showalter, B. M., Losman, J. A., Chen, X. P., Mostecki, J. W., Banks, A. S., Limnander, A., Fernandez, N., & Rothman, P. B. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.20.9092-9101.2004 · Cited by 47
The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma
Huang, Y., Zhang, Y., Ge, L., Lin, Y., & Kwok, H. F. (2018) · Cancers · doi:10.3390/cancers10030082 · Cited by 47
Are Janus kinase inhibitors superior over classic biologic agents in RA patients?
Kotyla, P. J. (2018) · BioMed Research International · doi:10.1155/2018/7492904 · Cited by 47
Growth hormone signalling: sprouting links between pathways, human genetics and therapeutic options
Pilecka, I., Whatmore, A. J., van Huijsduijnen, R. H., Destenaves, B., & Clayton, P. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.11.004 · Cited by 46
Novel Immunotherapeutic Avenues for Rheumatoid Arthritis
Semerano, L., Minichiello, É., Bessis, N., & Boissier, M. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.005 · Cited by 46
Allergen-induced production of IL-31 by canine Th2 cells and identification of immune, skin, and neuronal target cells
McCandless, E. E., Rugg, C. A., Fici, G. J., Messamore, J. E., Aleo, M. M., & Gonzales, A. J. (2013) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2013.10.017 · Cited by 45
Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis
Iwata, S., & Tanaka, Y. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1189826 · Cited by 45
Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases
Liu, Y., Gibson, S. A., Benveniste, E. N., & Qin, H. (2015) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2016015517 · Cited by 43
Increased Levels of Pro-Inflammatory and Anti-Inflammatory Cellular Responses in Parkinson’s Disease Patients: Search for a Disease Indicator
Yang, L., Guo, C., Zhu, J., Feng, Y., Chen, W.-L., Feng, Z.-Z., Wang, D., Sun, S., Lin, W., & Wang, Y. (2017) · Medical Science Monitor · doi:10.12659/msm.904240 · Cited by 43
Self-citation
Inhibition of Janus Kinase 2 and Signal Transduction and Activator of Transcription 3 Protect Against Cecal Ligation and Puncture-Induced Multiple Organ Damage and Mortality
Hui, L., Yao, Y., Wang, S., Yu, Y., Dong, N., Li, H., & Sheng, Z. (2009) · Journal of Trauma: Injury, Infection & Critical Care · doi:10.1097/ta.0b013e318164d05f · Cited by 42
STAT3 Dysregulation in Mature T and NK Cell Lymphomas
Seffens, A., Herrera, A. M., Tegla, C., Buus, T. B., Hymes, K. B., Ødum, N., Geskin, L. J., & Koralov, S. B. (2019) · Cancers · doi:10.3390/cancers11111711 · Cited by 42
Filgotinib for the treatment of rheumatoid arthritis
Taylor, P. C., Azeez, M., & Kiriakidis, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1372422 · Cited by 41
The Functions and Therapeutic Potential of Heat Shock Proteins in Inflammatory Bowel Disease—An Update
Hoter, A., & Naim, H. Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215331 · Cited by 41
Editorial: Decernotinib: A Next‐Generation Jakinib
Gadina, M., Schwartz, D. M., & O’Shea, J. J. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39463 · Cited by 40
VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions
Zetterberg, C., Maltais, F., Laitinen, L., Liao, S., Tsao, H., Chakilam, A., & Hariparsad, N. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.071100 · Cited by 40
Cytokines in canine inflammatory bowel disease
Kołodziejska-Sawerska, A., Rychlik, A., Depta, A., Wdowiak, M., Nowicki, M., & Kander, M. (2013) · Polish Journal of Veterinary Sciences · doi:10.2478/pjvs-2013-0025 · Cited by 39
Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster
Yamaoka, K. (2016) · Drug Safety · doi:10.1007/s40264-016-0430-0 · Cited by 39
Tofacitinib: A New Oral Therapy for Psoriasis
Azevedo, A., & Torres, T. R. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0596-y · Cited by 39
Efficacy of baricitinib in the treatment of rheumatoid arthritis
Richez, C., Truchetet, M., Kostine, M., Schaeverbeke, T., & Bannwarth, B. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359256 · Cited by 38
Baricitinib for the treatment of rheumatoid arthritis
Kubo, S., Nakayamada, S., & Tanaka, Y. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1214576 · Cited by 36
Ruxolitinib
Yang, L. P. H., & Keating, G. M. (2012) · Drugs · doi:10.2165/11209340-000000000-00000 · Cited by 33
Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors
Jaime‐Figueroa, S., de Vicente, J., Hermann, J. C., Jahangir, A. M., Jin, S., Kuglstatter, A., Lynch, S. M., Menke, J. G., Niu, L., Patel, V. P., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.015 · Cited by 33
Introduction to JAK/STAT signaling and the vasculature
Marrero, M. B. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.09.002 · Cited by 33
Systems biology of JAK/STAT signalling
Pfeifer, A. C., Timmer, J., & Klingmüller, U. (2008) · Essays in Biochemistry · doi:10.1042/bse0450109 · Cited by 33
Analysis of miRNA expression in patients with rheumatoid arthritis during remission and relapse after a 5-year trial of tofacitinib treatment
Fernández-Ruiz, J. C., Ramos-Remus, C., Sánchez‐Corona, J., Castillo-Ortiz, J. D., Castaneda-Sanchez, J. J., Bastián, Y., Romo-García, M. F., Ochoa-González, F. D. L., Monsiváis-Urenda, A. E., González‐Amaro, R., et al. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.07.028 · Cited by 32
STAT5a and STAT6 gene expression levels in multiple sclerosis patients
Hatami, M., Salmani, T., Arsang‐Jang, S., Omrani, M. D., Mazdeh, M., Ghafouri‐Fard, S., Sayad, A., & Taheri, M. (2017) · Cytokine · doi:10.1016/j.cyto.2017.10.022 · Cited by 31
The Effect of Verapamil, a P‐Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once‐Daily JAK Inhibitor
Zhu, T., Howieson, C., Wojtkowski, T., Garg, J. P., Han, D., Fisniku, O., & Keirns, J. J. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.344 · Cited by 29
Ocrelizumab for the treatment of multiple sclerosis
Bigaut, K., Seze, J. D., & Collongues, N. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1561284 · Cited by 29
Chemical JAK inhibitors for the treatment of rheumatoid arthritis
Nakayamada, S., Kubo, S., Iwata, S., & Tanaka, Y. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241237 · Cited by 28
National Institute for Health and Clinical Excellence
(2010) · Journal of Neonatal Nursing · doi:10.1016/j.jnn.2010.11.006 · Cited by 26
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
Sapre, M., Tremblay, D. A., Wilck, E. J., James, A., Leiter, A., Coltoff, A. R., Koshy, A. G., Kremyanskaya, M., Hoffman, R., Mascarenhas, J. O., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53056-x · Cited by 25
N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells
Dagvadorj, A., Tan, S., Liao, Z., Xie, J., Nurmi, M. J., Alanen, K. A., Rui, H., Mirtti, T. K., & Nevalainen, M. T. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.09.008 · Cited by 24
Endothelin-1 stimulates expression of cyclin D1 and S-phase kinase–associated protein 2 by activating the transcription factor STAT3 in cultured rat astrocytes
Kōyama, Y., Sumie, S., Nakano, Y., Nagao, T., Tokumaru, S., & Michinaga, S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005614 · Cited by 24
Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-γ through JAK/STAT pathway by translational regulation
Tamai, M., Kawakami, A., Tanaka, F., Miyashita, T., Nakamura, H., Iwanaga, N., Izumi, Y., Arima, K., Aratake, K., Huang, M., et al. (2006) · Journal of Laboratory and Clinical Medicine · doi:10.1016/j.lab.2005.12.001 · Cited by 22
Pharmacodynamic Analysis of Tofacitinib and Basiliximab in Kidney Allograft Recipients
Vafadari, R., Quaedackers, M. E., Kho, M. M. L., Mol, W. M., Chan, G. L., Weimar, W., & Baan, C. C. (2012) · Transplantation · doi:10.1097/tp.0b013e3182626b5a · Cited by 17
Calcineurin B in CD4+ T Cells Prevents Autoimmune Colitis by Negatively Regulating the JAK/STAT Pathway
Mencarelli, A., Vacca, M., Khameneh, H. J., Acerbi, E., Tay, A., Zolezzi, F., Poidinger, M., & Mortellaro, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00261 · Cited by 17
Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients
Nazdik, M. K., Taheri, M. N., Sajjadi, E., Arsang‐Jang, S., Koohpar, Z. K., Inoko, H., & Sayad, A. (2016) · Human Antibodies · doi:10.3233/hab-160296 · Cited by 16
GYF-21, an Epoxide 2-(2-Phenethyl)-Chromone Derivative, Suppresses Innate and Adaptive Immunity via Inhibiting STAT1/3 and NF-κB Signaling Pathways
Guo, R., Zhao, Y., Li, J., Gu, Y., Huo, H.-X., Li, S., Song, Y., Zhu, Z., & Tu, P. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00281 · Cited by 16
Multiple outcome meta-analysis of gene-expression data in inflammatory bowel disease
Vennou, K. E., Piovani, D., Kontou, P. I., Bonovas, S., & Bagos, P. G. (2019) · Genomics · doi:10.1016/j.ygeno.2019.09.019 · Cited by 15
Filgotinib in Crohn’s Disease: JAK Is Back
Danese, S., Fiorino, G., & Peyrin‐Biroulet, L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.040 · Cited by 14
Molecular components of JAK/STAT signaling pathway and its interaction with transcription machinery
Shaposhnikov, A. V., Комарьков, И. Ф., Lebedeva, L. A., & Shidlovskii, Y. V. (2013) · Molecular Biology · doi:10.1134/s0026893313030126 · Cited by 13
Intraarticular gene transfer of SPRY2 suppresses adjuvant-induced arthritis in rats
Zhang, W., Zhu, J., Du, Z., Yu, J., Xu, Y., & Wang, F. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-6618-x · Cited by 11
A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence
Wade, R., Hodgson, R. M., Biswas, M., Harden, M., & Woolacott, N. F. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0447-3 · Cited by 11
Daclizumab-induced encephalitis in multiple sclerosis
Bianchi, A., & Ciccarelli, O. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519845079 · Cited by 10
Immune characteristics study of AG490, a signal pathway inhibitor, in EAE model mice
Zhao, Z., Mao, Z., Yin, J., Shu, Y., Qiu, W., Lu, Z., & Hu, X. (2016) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2016.08.015 · Cited by 7
Inhibitors of JAK for the treatment of rheumatoid arthritis: rationale and clinical data
Malemud, C. J. (2011) · Clinical Investigation · doi:10.4155/cli.11.169 · Cited by 6
Ruxolitinib for the Treatment of Disease-Related Splenomegaly or Symptoms in Adult Patients with Myelofibrosis
Liew, E., & Lipton, J. H. (2014) · International Journal of Hematologic Oncology · doi:10.2217/ijh.14.35 · Cited by 1

Flagged first, then by citations

2 of the 184 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

Seif, 2017, The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells, Cell Commun. Sign., 15, 1
Oshea, 2015, The JAK-STAT pathway: impact on human disease and therapeutic intervention*, Annu. Rev. Med., 66, 311, 10.1146/annurev-med-051113-024537 · DOI
Yan, 2018, Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases, Clin. Immunol., 189, 4, 10.1016/j.clim.2016.09.014 · DOI · Paper page

Sorted by citations

The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Microglia polarization from M1 to M2 in neurodegenerative diseases
Guo, S., Wang, H., & Yin, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.815347 · Cited by 920
Signaling pathways and targeted therapy for myocardial infarction
Zhang, Q., Wang, L., Wang, S., Cheng, H., Xu, L., Pei, G., Wang, Y., Fu, C., Jiang, Y., He, C., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00925-z · Cited by 882
Self-citation
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Chen, X., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 797
Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy
Liu, J., Han, X., Zhang, T., Tian, K., Li, Z., & Luo, F. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01512-7 · Cited by 742

See all 1,010

Authors: Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S.
Affiliations: Harbin Medical University (CN)
China Pharmaceutical University (CN)
Southeast University (CN)
Corresponding author: Sun, Shiqin
ORCID: Xin, Ping
Wang, Youzhi
Venue: International Immunopharmacology
Publisher: Elsevier BV
Published: 2020-03
Volume: 80
Pages: 106210
ISSN: 1567-5769 (ISSN-L)
DOI: 10.1016/j.intimp.2020.106210
OpenAlex: W3001733563
Cited by: 1,010
References: 184
Citations by year: 2026: 125 · 2025: 229 · 2024: 224 · 2023: 195 · 2022: 160 · 2021: 56 · 2020: 20
FWCI: 11.60
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: International Immunopharmacology (publishedVersion)
PubMed (publishedVersion)
Funders: Fundamental Research Funds for the Central Universities (2018XN-25, JFWLD201904)
National Natural Science Foundation of China (81903763)
China Postdoctoral Science Foundation (2019M661312)
Natural Science Foundation of Heilongjiang Province (YQ2019H005)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: JAK/STAT signaling, JAK inhibitors, STAT proteins, JAK kinases, inflammatory diseases, cancer, immune regulation, signaling crosstalk, cell proliferation and differentiation, apoptosis
MeSH terms: Animals, Disease Models, Animal, Humans, Immune System Diseases, Inflammation, Signal Transduction, Cytokines, Protein Kinase Inhibitors, STAT Transcription Factors, Janus Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The role of JAK/STAT signaling pathway and its inhibitors in diseases.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks